Synthesis and biological evaluation of new nanomolar competitive inhibitors of Helicobacter pylori type II dehydroquinase. Structural details of the role of the aromatic moieties with essential residues

Journal of Medicinal Chemistry

Volumn 53, Issue 1, 2010, Pages 191-200

  Prazeres, Verónica F V ^a   Tizón, Lorena ^a   Otero, José M ^a   Guardado Calvo, Pablo ^a   Llamas Saiz, Antonio L ^a   Van Raaij, Mark J ^a,b   Castedo, Luis ^a   Lamb, Heather ^c   Hawkins, Alastair R ^c   González Bello, Concepción ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIAL ENZYME; DEHYDROQUINASE; DEHYDROQUINASE INHIBITOR; SHIKIMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CATALYSIS; COMPETITIVE INHIBITION; DRUG BINDING SITE; DRUG SYNTHESIS; ENZYME ACTIVE SITE; ENZYME INHIBITOR INTERACTION; HELICOBACTER PYLORI; REACTION ANALYSIS; STRUCTURE ACTIVITY RELATION;

ALCOHOLS; BINDING, COMPETITIVE; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HELICOBACTER PYLORI; HYDRO-LYASES; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 74849120539     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9010466     Document Type: Article

References (53)

1. (a) Arias, C. A.; Murray, B. E. Antibiotic-resistant bugs in the 21st century. A clinical super-challenge. N. Engl. J. Med. 2009, 360, 439-443.
2. (b) Jayaraman, R. Bacterial persistence: some new insights into an old phenomenon. J. Biosci. 2008, 33, 795-805.
3. (a) Giamarellou, H. Treatment options for multidrug-resistant bacteria. Expert Rev. Anti-Infect. Ther. 2006, 4, 601-618.
4. (b) Appelbaum, P. C.; Jacobs, M. R. Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. Curr. Opin. Microb. 2005, 8, 510-517.
5. Okeke, I. N.; Klugman, K. P.; Bhutta, Z. A.; Duse, A. G.; Jenkins, P.; O'Brien, T. F.; Pablos-Mendez, A.; Laxminarayan, R. Antimicrobial resistance in developing countries. Part II: Strategies for containment. Lancet Infect. Dis. 2005, 5, 568-580.
6. Graham, D. Y.; Shiotani, A. New concepts of resistance in the treatment of Helicobacter pylori infections. Nat. Clin. Pract. Gastroenterol. Hepatol. 2008, 5, 321-331.
7. Duck, W. M.; Sobel, J.; Pruckler, J. M.; Song, Q.; Swerdlow, D.; Friedman, C.; Sulka, A.; Swaminathan, B.; Taylor, T.; Hoekstra, M.; Griffin, P.; Smoot, D.; Peek, R.; Metz, D. C.; Bloom, P. B.; Goldschmid, S.; Parsonnet, J.; Triadafilopoulos, G.; Pérez-Pérez, G. I.; Vakil, N.; Ernst, P.; Czinn, S.; Dunne, D.; Gold, B. D. Antimicrobial resistance incidence and risk factors among Helicobacter pylori-infected persons, United States. Emerg. Infect. Dis. 2004, 10, 1088-1094.
8. Megraud, F. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004, 53, 1374-1384.
9. Bruce, M. G.; Bruden, D. L.; McMahon, B. J.; Hennessy, T. W.; Reasonover, A.; Morris, J.; Hurlburt, D. A.; Peters, H.; Sacco, F.; Martínez, P.; Swenson, M.; Berg, D. E.; Parks, D.; Parkinson, A. J. Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003. Helicobacter 2006, 11, 581-588.
10. Hatakeyama, M. Helicobacter pylori and gastric carcinogenesis. J. Gastroenterol. 2009, 44, 239-248.
11. Gonzalez-Bello, C.; Castedo, L. Progress in type II dehydroquinase inhibitors: From concept to practice. Med. Res. Rev. 2007, 27, 177-208.
12. Haslam, E. The Shikimate Pathway; Wiley: New York, 1974.
13. Abell, A. Enzymology and Molecular Biology of the Shikimate Pathway. In Comprehensive Natural Products Chemistry; Sankawa, U., Ed.; Elsevier Science Ltd.: Oxford, U.K., 1999; pp 573-607.
14. (a) Roberts, F.; Roberts, C. W.; Johnson, J. J.; Kyle, D. E.; Krell, T.; Coggins, J. R.; Coombs, G. H.; Milhous, W. K.; Tzipori, S.; Ferguson, D. J.; Chakrabarti, D.; McLeod, R. Evidence for the shikimate pathway in apicomplexan parasites. Nature 1998, 393, 801-805.
15. (b) Keeling, P. J.; Palmer, J. D.; Donald, R. G.; Roos, D. S.; Waller, R. F.; McFadden, G. I. Shikimate pathway in apicomplexan parasites. Nature 1999, 397, 219-220.
16. Campbell, S. A.; Richards, T. A.; Mui, E. J.; Samuel, B. U.; Coggins, J. R.; McLeod, R.; Roberts, C.W. A complete shikimate pathway in Toxoplasma gondii: an ancient eukaryotic innovation. Int. J. Parasitol. 2004, 34, 5-13.
17. Roberts, C.W.; Roberts, F.; Lyons, R. E.; Kirisits, M. J.; Mui, E. J.; Finnerty, J.; Johnson, J. J.; Ferguson, D. J.; Coggins, J. R.; Krell, T.; Coombs, G. H.; Milhous, W. K.; Kyle, D. E.; Tzipori, S.; Barnwell, J.; Dame, J. B.; Carlton, J.; McLeod, R. The shikimate pathway and its branches in apicomplexan parasites. J. Infect. Dis. 2002, 185 (Suppl. 1), S25-S36.
18. (e) McConkey, G. A.; Pinney, J. W.; Westhead, D. R.; Plueckhahn, K.; Fitzpatrick, T. B.; Macheroux, P.; Kappes, B. Annotating the Plasmodium genome and the enigma of the shikimate pathway. Trends Parasitol. 2004, 20, 60-65.
19. (a) Salama, N. R.; Shepherd, B.; Falkow, S. Global transposon mutagenesis and essential gene analysis of Helicobacter pylori. J. Bacteriol. 2004, 186, 7926-7935.
20. (b) Sassetti, C. M.; Boyd, D. H.; Rubin, E. J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microb. 2003, 48, 77-84.
21. de Berardinis, V.;Vallenet, D.; Castelli,V.; Besnard, M.; Pinet, A.; Cruaud, C.; Samair, S.; Lechaplais, C.; Gyapay, G.; Richez, C.; Durot, M.; Kreimeyer, A.; Le Fèvre, F.; Schächter,V.; Pezo,V.;Döring,V.; Scarpelli, C.;Médigue, C.; Cohen, G. N.; Marlière, P.; Salanoubat, M.; Weissenbach, J. A complete collection of single-gene deletion mutants of Acinetobacter baylyi ADP1. Mol. Syst. Biol. 2008, 4, 1-15.
22. For a database of essential bacterial genes, see the following: (a) www.essentialgene.org.
23. (b) Zhang, R.; Lin, Y.DEG5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res. 2009, 37, D455-D458.
24. (c) Zhang, R.; Ou, H.-Y.; Zhang, C.-T. DEG: a database of essential genes. Nucleic Acids Res. 2004, 32, D271-D272.
25. Kleanthous, C. K.; Deka, R.; Davis, K.; Kelly, S. M.; Cooper, A.; Harding, S. E.; Price, N. C.; Hawkins, A. R.; Coggins, J. R. A comparison of the enzymological and biophysical properties of two distinct classes of dehydroquinase enzymes. Biochem. J. 1992, 282, 687-695.
26. Shneier, A.; Harris, J.; Kleanthous, C.; Coggins, J. R.; Hawkins, A. R.; Abell, C. Evidence for opposite stereochemical courses for the reactions catalyzed by type I and type II dehydroquinases. Bioorg. Med. Chem. Lett. 1993, 3, 1399-1402.
27. (a) Duncan, K.; Chaudhuri, S.; Campbell,M. S.; Coggins, J. R. The overexpression and complete amino acid sequence of Escherichia coli 3-dehydroquinase. Biochem. J. 1986, 238, 475-483.
28. (b) Servos, S.; Chatfield, S.; Hone, D.; Levine, M.; Dimitriadis, G.; Pickard, D.; Dougan, G.; Fairweather, N.; Charles, I. G. Molecular cloning and characterization of the aroD gene encoding 3-dehydroquinase from Salmonella typhi. J. Gen. Microbiol. 1991, 137, 147-152.
29. (a) Moore, J. D.; Lamb, H. K.; Garbe, T.; Servos, S.; Dougan, G.; Charles, I. G.; Hawkins, A. R. Inducible overproduction of the Aspergillus nidulans pentafunctionalAROMprotein and the type-I and -II 3-dehydroquinases from Salmonella typhi and Mycobacterium tuberculosis. Biochem. J. 1992, 287, 173-181.
30. (b) Garbe, T.; Servos, S.; Hawkins, A. R.; Dimitriadis, G.; Young, D.; Dougan, G.; Charles, I. The Mycobacterium tuberculosis shikimate pathway genes: evolutionary relationship between biosynthetic and catabolic 3-dehydroquinases. Mol. Gen. Genet. 1991, 228, 385-392.
31. Bottomley, J. R.; Clayton, C. L.; Chalk, P. A.; Kleanthous, C. Cloning, sequencing, expression, purification and preliminary characterization of a type II dehydroquinase from Helicobacter pylori. Biochem. J. 1996, 319, 559-565.
32. White, P. J.;Young, J.;Hunter, I. S.;Nimmo,H.G.; Coggins, J. R. The purification and characterization of 3-dehydroquinase from Streptomyces coelicolor. Biochem. J. 1990, 265, 735-738.
33. (a) Roszak, A. W.; Robinson, D. A.; Krell, T.; Hunter, I. S.; Frederickson, M.; Abell, C.; Coggins, J. R.; Lapthorn, A. J. The structure and mechanism of the type II dehydroquinase from Streptomyces coelicolor. Structure 2002, 10, 493-503.
34. (b) Harris, J.; González-Bello, C.; Kleanthous, C.; Coggins, J. R.; Hawkins, A. R.; Abell, C. Evidence from kinetic isotope studies for an enolate intermediate in the mechanism of type II dehydroquinases. Biochem. J. 1996, 319, 333-336.
35. Krell, T.; Horsburgh, M. J.; Cooper, A.; Kelly, S. M.; Coggins, J. R. Localization of the active site of type II dehydroquinase. Identification of a common arginine-containing motif in the two classes of dehydroquinases. J. Biol. Chem. 1996, 271, 24492-24497.
36. Krell, T.; Pitt, A. R.; Coggins, J. R. The use of electrospray mass spectrometry to identify an essential arginine residue in type II dehydroquinases. FEBS Lett. 1995, 360, 93-96.
37. Payne, R. J.; Riboldi-Tunnicliffe, A. L.; Kerbarh, V. V. V.; Abell, A. D.; Lapthorn, A. J.; Abell, C. Design, synthesis, and structural studies on potent biaryl inhibitors of type II dehydroquinases. ChemMedChem 2007, 2, 1010-1013.
38. Sánchez-Sixto, C.; Prazeres, V. F.; Castedo, L.; Suh, S. W.; Lamb, H.; Hawkins, A. R.; Cañada, F. J.; Jiménez-Barbero, J.; González-Bello, C. Competitive Inhibitors of Helicobacter pylori type II dehydroquinase: synthesis, biological evaluation, and NMR studies. ChemMedChem 2008, 3, 756-770.
39. Śanchez-Sixto, C.; Prazeres, V. F. V.; Castedo, L.; Lamb, H.; Hawkins, A. R.; Gonźalez-Bello, C. Structure-based design, synthesis and biological evaluation of inhibitors of Mycobacterium tuberculosis type II dehydroquinase. J. Med. Chem. 2005, 48, 4871-4881.
40. (a) Dixon, M. The determination of enzyme inhibitor constants. J. Am. Chem. Soc. 1953, 55, 170-171.
41. (b) Enzymes and Their Inhibition, Drug Development; Smith, H. J., Simons, C., Eds.; CRC Press: Boca Raton, FL, 2005; pp 156-161.
42. Robinson, D. A.; Stewart, K. A.; Price, N. C.; Chalk, P. A.; Coggins, J. R.; Lapthorn, A. J. Crystal structures of Helicobacter pylori type II dehydroquinase inhibitor complexes: new directions for inhibitor design. J. Med. Chem. 2006, 49, 1282-1290.
43. http://www.ccdc.cam.ac.uk/products/life-sciences/gold/.
44. Leslie, A. G. The integration of macromolecular diffraction data. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 48-57.
45. (28) Evans, P. Scaling and assessment of data quality. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 72-82.
46. Winn, M. D. An overview of the CCP4 project in protein crystallography: an example of a collaborative project. J. Synchrotron Radiat. 2003, 10, 23-25.
47. McCoy, A. J.; Grosse-Kunstleve, R. W.; Adams, P. D.; Winn, M. D.; Storoni, L. C.; Read, R. J. Phaser crystallographic software. J. Appl. Crystallogr. 2007, 40, 658-674.
48. Brunger, A. T. Free R value: cross-validation in crystallography. Methods Enzymol. 1997, 277, 366-396.
49. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132.
50. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255.
51. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B., 3rd; Snoeyink, J.; Richardson, J. S.; Ricchardson, D. C. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007, 35, W375-W383.
52. DeLano, W. L. The PyMOL Molecular Graphics System; DeLano Scientific LLC, Palo Alto, CA, 2008; http://www.pymol.org.
53. Theoretical and Computational Biophysics Group at the Beckman Institute, University of Illinois at Urbana - Champaign. http://www.ks.uiuc.edu/.